CLM-SAP 18: Translational Science of the LDL Receptor
Cardiology
Credits:
3 ACPE 3 ANCC Contact Hours 3 CDR 3 AMA PRA Category 1 Credit(s) ™
3 ACPE 3 ANCC Contact Hours 3 CDR 3 AMA PRA Category 1 Credit(s) ™
Launch Date:
January 23, 2017
January 23, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists, Dietitians, PhDs, Physicians Assistants, Primary Care Physicians
Relevant Terms:
Low-Density Lipoprotein
See Faculty section below for a complete list of faculty.
See Faculty section below for a complete list of faculty.
Bio| 1. | Discuss the history of discovery of the LDL receptor | 2. | Outline the LDL receptors, metabolic pathways, and their pleiotropic effects |
| 3. | Describe the role of proprotein convertase subtilisin/kexin type 9 in lipoprotein metabolism including the LDL receptor and other receptor interactions | 4. | Describe genomic technology and the science of screening for mutations and genes that cause FH |
| 5. | Interpret complex case reviews including differential diagnosis of LDLr disorders | 6. | Outline factors having an impact on cardiovascular risk in patients with LDL disorders |
| 7. | Discuss clinical utility of Genetic testing for LDLr disorders | 8. | Discuss the updated knowledge of Lp(a) metabolism, including production and clearance |
| 9. | Discuss the current view on atherogenicity of Lp(a) and contribution to CVD risk | 10. | Discuss modalities of therapeutic interventions to lower Lp(a) levels in plasma |
| 11. | Identify the genetic causes of LDL disorders, including the clinical implications of these genetic disorders | 12. | Evaluate the clinical effects, safety, and efficacy data for current treatment options for patients with lipid disorders |
| 13. | Recognize the role of current therapeutic approaches for management of lipid disorders | 14. | Evaluate the efficacy and safety of PCSK9 inhibitors, lomitapide, and mipomersen in treating lipid disorders |
| 15. | Recognize the role of emerging therapies for the treatment of patients with LDLr disorders |
| 1. | Discuss the history of discovery of the LDL receptor |
| 2. | Outline the LDL receptors, metabolic pathways, and their pleiotropic effects |
| 3. | Describe the role of proprotein convertase subtilisin/kexin type 9 in lipoprotein metabolism including the LDL receptor and other receptor interactions |
| 4. | Describe genomic technology and the science of screening for mutations and genes that cause FH |
| 5. | Interpret complex case reviews including differential diagnosis of LDLr disorders |
| 6. | Outline factors having an impact on cardiovascular risk in patients with LDL disorders |
| 7. | Discuss clinical utility of Genetic testing for LDLr disorders |
| 8. | Discuss the updated knowledge of Lp(a) metabolism, including production and clearance |
| 9. | Discuss the current view on atherogenicity of Lp(a) and contribution to CVD risk |
| 10. | Discuss modalities of therapeutic interventions to lower Lp(a) levels in plasma |
| 11. | Identify the genetic causes of LDL disorders, including the clinical implications of these genetic disorders |
| 12. | Evaluate the clinical effects, safety, and efficacy data for current treatment options for patients with lipid disorders |
| 13. | Recognize the role of current therapeutic approaches for management of lipid disorders |
| 14. | Evaluate the efficacy and safety of PCSK9 inhibitors, lomitapide, and mipomersen in treating lipid disorders |
| 15. | Recognize the role of emerging therapies for the treatment of patients with LDLr disorders |
RELEASE DATE: January 23rd, 2017
EXPIRATION DATE: January 23rd, 2020
FEE: There is no fee for this activity.
ACTIVITY FORMAT: Internet activity enduring material
CRITERIA FOR SUCESS
In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. To receive credit you must obtain a 30% or greater total score on your Performance Score Report. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at cme@lipid.org.
For Pharmacists: Upon successfully completing the post-test with a score of 30% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
COMMERCIAL SUPPORT
This educational activity is supported by educational grants from Merck Sharp & Dohme Corp. and Sanofi US and Regeneron Pharmaceuticals.
CREDIT DESIGNATION
CME credit provided by the National Lipid Association Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this enduring activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 3 Continuing Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.
CE Credit provided by Postgraduate Institute for MedicinePharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Universal Activity Number 0809-9999-17-374-H01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 3 contact hour(s) (0.3 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing
This educational activity for 3 contact hours is provided by the Postgraduate Institute for Medicine.
This educational activity for 3 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
COMMERCIAL SUPPORT
There is no commercial support for this activity.
PROGRAM FACULTY
Sergio Fazio, MD, PhD, FNLA
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
The William and Sonja Connor
Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Anne C. Goldberg, MD, FACP, FNLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Nathan O. Stitziel, MD, PhD
Assistant Professor of Medicine and Genetics
Director, Center for Cardiovascular Genetics
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine
St. Louis, MO
Director, Center for Cardiovascular Genetics
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine
St. Louis, MO
DISCLOSURES
Sergio Fazio, MD, PhD, FNLA
Consultant- Aegerion Pharmaceuticals Inc, BASF Corporation, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., New Haven Pharmaceuticals, Inc., sanofi-aventis U.S.
Anne C. Goldberg, MD, FACP, FNLA
Contracted Research- Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, ISIS (IONIS), Merck & Co., Inc., Pfizer, Regeneron, Regeneron/ sanofi-aventis
Consultant- OptumRX , Sanofi/ Regeneron
Scholarly Contributions- Merck & Co., Inc.
Contracted Research- Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, ISIS (IONIS), Merck & Co., Inc., Pfizer, Regeneron, Regeneron/ sanofi-aventis
Consultant- OptumRX , Sanofi/ Regeneron
Scholarly Contributions- Merck & Co., Inc.
Nathan O. Stitziel, MD, PhD
Consultant- Aegerion Pharmaceuticals, Inc.
Contracted Research- AstraZeneca
NLA staff has nothing to disclose.
PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
